Please login to the form below

Not currently logged in
Email:
Password:

Hydra Biosciences and Pfizer sign global R&D novel ion-channel agreement

Hydra Biosciences signs a collaboration agreement with Pfizer Global R&D to develop TRPV3-antagonist products for pain

Hydra Biosciences has signed a collaboration agreement with Pfizer Global R&D to develop TRPV3-antagonist product candidates for pain.

Per the agreement, US-based Hydra will receive upfront and success-based development milestone payments of USD 195m for the first developed product launched and more for additional approved indications.

Pfizer will fund all R&D under the agreement and will receive exclusive access to Hydra's current TRPV3 patents as well as an exclusive license to commercialise any compound from the collaboration. Once the products are on the market, Pfizer will pay worldwide royalties to Hydra.

Recent research on Transient Receptor Potential (TRP) antagonists indicates that they may act as multimodal signal integrators. Since TRP channels are only distantly related to voltage gated channels and homology among TRP family members is quite low, it is anticipated that specific and selective modulators may be more readily identified in this family than in other ion channel groups, limiting the potential for off-target effects, which have proven problematic in other ion channel families, such as Vioxx (rofecoxib) and other COX-2 inhibitors.

30th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics